Immunome Stock Quote IMNM - Stock Price, News, Charts, Message Board, Trades

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Immunome Inc (IMNM) Quote

Immunome Inc (IMNM)

14.16

0.67

(4.97%)

Closed July 16 4:00PM

Delayed by 15 minutes

14.28

0.12

(0.85%)

After Hours: 7:59PM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

14.28

Bid

13.66

Ask

14.29

Volume

494,560

13.44 Day's Range 14.24

6.13 52 Week Range 30.958

Market Cap

Previous Close

13.49

Open

13.58

Last Trade

Last Trade Time

Financial Volume

$ 6,879,751

VWAP

13.9109

Average Volume (3m)

878,125

Shares Outstanding

59,968,868

Dividend Yield

-

PE Ratio

-7.95

Earnings Per Share (EPS)

-1.78

Revenue

14.02M

Net Profit

-106.81M

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.immunome.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was $13.49. Over the last year, Immunome shares have traded in a share price range of $ 6.13 to $ 30.958.

Immunome currently has 59,968,868 shares outstanding. The market capitalization of Immunome is $808.98 million. Immunome has a price to earnings ratio (PE ratio) of -7.95.

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.16	17.8217821782	12.12	14.24	11.95	618821	12.64617527	CS
4	-0.67	-4.48160535117	14.95	14.975	11.07	1012896	12.40138568	CS
12	-1.78	-11.0834371108	16.06	16.79	11.07	878125	13.94060532	CS
26	0.78	5.77777777778	13.5	30.958	11.07	817787	17.8367603	CS
52	6.46	82.6086956522	7.82	30.958	6.13	461797	16.7209265	CS
156	-1.62	-10.1886792453	15.9	30.958	2.09	245623	15.19074325	CS
260	-1.38	-8.8122605364	15.66	63.78	2.09	224123	16.94088428	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
SHOTWSafety Shot Inc	$ 0.41 (115.79%)	7.56k
DATSDatChat Inc	$ 1.89 (81.73%)	54.75M
CYNCYNGN Inc	$ 9.18 (53.77%)	17.79M
SCNIScinai Immunotherapeutics Ltd	$ 5.80 (42.86%)	29.37M
ASLNASLAN Pharmaceuticals Ltd	$ 1.36 (-46.67%)	1.16M
KZIAKazia Therapeutics Ltd	$ 0.5593 (-37.56%)	15.34M
LCFYLocafy Ltd	$ 3.5597 (-36.32%)	584.38k
NAASNaaS Technology Inc	$ 2.82 (-33.02%)	1.94M
ZENVZenvia Inc	$ 1.67 (-26.75%)	658.26k
FFIEFaraday Future Intelligent Electric Inc	$ 0.5152 (22.09%)	217.92M
NVDANVIDIA Corporation	$ 128.44 (-0.62%)	208.32M
SQQQProShares UltraPro Short QQQ	$ 7.46 (-0.67%)	155.14M
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
TSLATesla Inc	$ 252.64 (1.78%)	147.31M

Monksdream

Monksdream 4 months ago

IMNM 10Q due 3/22

Monksdream

Monksdream 4 months ago

IMNM new 52 week hi

Monksdream

Monksdream 6 months ago

IMNM new 52 week high

OncoJock

OncoJock 7 months ago

Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ

OncoJock

OncoJock 7 months ago

Laster

Laster 10 months ago

Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.

Laster

Laster 10 months ago

I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.

wiwineguy

wiwineguy 1 year ago

Ha, sold in fall of 21 for $25.

makinezmoney

makinezmoney 1 year ago

$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

GO $IMNM

makinezmoney

makinezmoney 1 year ago

$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50

Offfffffffffff she goes.

Nice boomer

GO $IMNM

Awl416

Awl416 1 year ago

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

wiwineguy

wiwineguy 3 years ago

you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu

Harbor6460

Harbor6460 3 years ago

They cannot dilute on the bid. Only the ask

Pedro2004

Pedro2004 3 years ago

Pulled down to under $20.00

Pedro2004

Pedro2004 3 years ago

They pulled this down to under $21.00

I'm back-in at $21.00

Major_Bankz

Major_Bankz 3 years ago

$22.50 U worry too much, should be $25+ this afternoon IMO

Pedro2004

Pedro2004 3 years ago

I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.

Pedro2004

Pedro2004 3 years ago

This run could have broke $30 today. But the company killed-it.

Major_Bankz

Major_Bankz 3 years ago

yep, shorties portfolio will get destroyed here.

Pedro2004

Pedro2004 3 years ago

The dilution is going to kill this run.

Pedro2004

Pedro2004 3 years ago

Looks like the company is dumping shares on the bid.

Major_Bankz

Major_Bankz 3 years ago

I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO

Major_Bankz

Major_Bankz 3 years ago

Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO

Major_Bankz

Major_Bankz 3 years ago

Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.

Major_Bankz

Major_Bankz 3 years ago

IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Adamant DRI Processing a... (CE)

Bnp Paribas Issuance

NLBNPIT259C3 20991231 62...

NLBNPIT259K6 20991231 32...

NLBNPIT23DF8 20241220 16

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions